---
schema_version: "secwatch.filing_event.v1"
accession: "0001601485-25-000006"
form_type: "8-K"
ticker: "ELTX"
cik: "0001601485"
company_name: "Elicio Therapeutics, Inc."
filed_at: "2025-01-22T23:59:59+00:00"
generated_at: "2026-05-27T19:31:30.498677+00:00"
event_type: "regulatory"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Elicio receives supportive FDA feedback on ELI-002 Phase 3 registrational strategy

## Summary
- FDA aligned on Phase 3 study design: dose, schedule, patient population (KRAS-mutated pancreatic cancer), and DFS endpoint.
- Phase 2 AMPLIFY-7P study fully enrolled; interim DFS analysis expected H1 2025.
- Positive Phase 2 results could support rapid advancement into Phase 3 and potential BLA filing.
- ELI-002 is an off-the-shelf monotherapy for mKRAS cancers patients post-chemotherapy.

## SEC filing metadata
- accession: 0001601485-25-000006
- form_type: 8-K
- ticker: ELTX
- cik: 0001601485
- company_name: Elicio Therapeutics, Inc.
- filed_at: 2025-01-22T23:59:59+00:00
- event_type: regulatory
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1601485/000160148525000006/0001601485-25-000006-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1601485/000160148525000006/angn-20250122.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001601485-25-000006
- JSON: https://secwatch.observer/filing/0001601485-25-000006.json
- Plain text: https://secwatch.observer/filing/0001601485-25-000006.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.